^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combing Immune Checkpoint Inhibitors with Radiotherapy in Advanced Non-small-cell Lung Cancer
Published date:
08/08/2023
Excerpt:
The efficacy and safety of PD-1 inhibitors immunotherapy plus radiotherapy were evaluated….In an exploratory analysis, patients with PD-L1≥50%,ECOG performance status≤1,EQD2≤20Gy,irradiated tumor site with lung ,male,higher Albumin to achieve favorable survival benefits.
Source:
Title:
Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer.
Published date:
05/25/2023
Excerpt:
Among LTR compared to patients with best response of PD, dNLR < 3.0 (OR 1.72, p = 0.030), high PD-L1 (OR 5.23, p < 0.001), and high TMB (OR 2.55, p = 0.001) associated with LTR.
DOI:
10.1200/JCO.2023.41.16_suppl.9107
Source:
Title:
Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice
Published date:
06/07/2022
Excerpt:
166 patients with aNSCLC receiving PD-(L)1 inhibitor monotherapy met inclusion criteria....In the weighted analysis, having a very high PDL1+e was associated with lower mortality (weighted hazard ratio 0.57, 95% CI 0.36-0.90) and longer median survival: 3.85 vs 1.49 years….Very high PD-L1+e (≥90%) was associated with an overall survival benefit over high PD-L1+e (50-89%) in patients receiving first-line PD-(L)1 inhibitor monotherapy in a model controlling for potential confounders.
DOI:
https://doi.org/10.1002/pds.5487
Source:
Title:
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
Published date:
03/26/2021
Excerpt:
...we aimed to evaluate the efficacy of first-line anti-PD-(L)1 monotherapy in advanced NSCLC patients with high PD-L1 expression (≥50%) compared to platinum-based chemotherapy….In conclusion, PD-(L)1 inhibitor monotherapy improves efficacy outcomes in the first line setting of advanced NSCLC patients with high PD-L1 expression.
DOI:
10.3390/jcm10071365
Source:
Title:
131P - Predictive factors of response to PD-(L)1 inhibitors in patients with advanced non-small cell lung (NSCLC) and high PD-L1 expression
Published date:
03/17/2021
Excerpt:
...pts with advanced NSCLC and high PD-L1 expression treated with PD-(L)1 inhibitors…ORR and DCR in overall patients were 57% and 72.7%, respectively and ORR and DCR in pts treated in first line were 57.6% and 73.4%, respectively.
